Amicogen amends paid-in capital increase details
아미코젠
092040
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2719
Risk-adjusted indicator based on 2719 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Amendment Date: June 23, 2026
- • Original Filing Date: June 22, 2026
- • Financial Unit Correction: From KRW to 1M KRW
AI Analysis Summary
Amicogen, Inc. filed an amendment to its Material Fact Report regarding a paid-in capital increase. The primary change is a correction in the unit for financial figures from KRW to 1M KRW. The report indicates that upon completion of this capital increase, YK Bio Nova Holdings Co., Ltd. is expected to become the largest shareholder. New shares will be subject to a one-year lock-up period. The issuance price will be determined using a 10% discount rate based on the weighted average stock price from the 3rd to 5th trading days prior to the subscription date (June 22, 2026). The amendment itself is a procedural correction, thus having a neutral financial impact.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.